Skip to main content
IN8BIO, INC. logo

IN8BIO, INC. — Investor Relations & Filings

Ticker · INAB ISIN · US45674E1091 LEI · 549300H68IVCRKSGSL94 US Manufacturing
Open in API
Filings indexed 382 across all filing types
Latest filing 2026-06-01 Capital/Financing Update
Country US United States of America
Listing US INAB

About IN8BIO, INC.

https://www.in8bio.com

IN8BIO, INC. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for solid and hematological tumors. The company's proprietary DeltEx™ platform utilizes allogeneic, autologous, and genetically modified approaches to develop novel cell therapies. IN8BIO was the first to advance genetically modified gamma-delta T cells into clinical trials. Its lead product candidates include INB-400, a Phase 2 asset for newly diagnosed glioblastoma (GBM), and INB-100, a Phase 1 candidate for patients with leukemia undergoing hematopoietic stem cell transplantation. The company is also advancing a broad portfolio of preclinical programs focused on solid tumors.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 91% confidence The document is a Form 8-K current report by IN8bio, Inc. announcing the entry into an at-the-market equity offering sales agreement (an equity financing arrangement) and termination of a prior sales agreement. This constitutes a financing activity update, fitting the Capital/Financing Update category.
2026-06-01 English
424B5
Capital/Financing Update Classification · 85% confidence The text is a Form 424B5 prospectus supplement and related base prospectus for an at-the-market equity offering of common stock (up to $2.8M) under a capital-on-demand sales agreement. It is clearly a document facilitating a new share issuance and financing activity, not an annual report or earnings release. This matches the “Capital/Financing Update” category (CAP).
2026-06-01 English
S-3/A
Regulatory Filings Classification · 75% confidence The document is a Form S-3/A “Amendment No. 1 to Registration Statement on Form S-3” filed with the SEC under the Securities Act of 1933. It is a shelf registration statement prospectus for offerings of common stock, preferred stock, debt securities, warrants, rights, and units up to $200 million. This is a regulatory compliance filing rather than an annual/interim report, earnings release, governance doc, or capital update press release. It falls under the general SEC regulatory filings category (fallback) rather than one of the more specific financial report or announcement types.
2026-05-18 English
S-8 POS - IN8BIO, INC. (0001740279) (Filer)
Regulatory Filings Classification · 85% confidence The document is a post-effective amendment to Form S-8 registration statements filed with the U.S. SEC for equity incentive plans. This is a regulatory compliance filing (registration of securities) rather than an annual or quarterly report, earnings release, board change, proxy, or dividend notice. It does not contain financial statements or capital markets updates but is a standard SEC registration statement, which falls under the general Regulatory Filings category (RNS).
2026-05-07 English
S-8 POS - IN8BIO, INC. (0001740279) (Filer)
Regulatory Filings Classification · 85% confidence The document is a post-effective amendment to Form S-8 registration statements filed under the Securities Act of 1933 to register shares for an equity incentive plan. Form S-8 is a regulatory compliance filing and does not correspond to any of the other more specific report types (e.g., Annual Report, Earnings Release, Proxy Statement). Therefore, it falls under the general Regulatory Filings category (RNS) as a miscellaneous SEC filing.
2026-05-07 English
S-8 POS - IN8BIO, INC. (0001740279) (Filer)
Share Issue/Capital Change Classification · 92% confidence The document is a Post-Effective Amendment No. 1 and No. 2 to Form S-8, which is a registration statement to register shares of common stock issuable under equity incentive plans. Form S-8 relates to employee share issuances under capital plans. There is no mention of dividends, proxies, earnings, or management changes. This is a direct registration of new share issuance capacity under the company’s equity plans, corresponding to category “Share Issue/Capital Change.”
2026-05-07 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.